BioFinlandin jäsen

RNatives, Inc. is a US-based RNA activation (saRNA) therapeutics platform company and RNatives Oy is it's subsidiary operating R&D unit in Kuopio. The RNA activation (saRNA) platform enables the modulation of a target gene expression in target cells by nuclear microRNA (miRNA) biology. The new miRNA biology was discovered by our Founder, Mikko Turunen, and his research group after years of basic research work. The Company's lead program is focusing on Heart Failure (HF) and Peripheral Artery Disease (PAD). The technology upregulates Vascular Endothelial Growth Factor A (VEGFA) expression in the affected tissue by novel miRNA for driving the new blood vessel formation and recovery from the disease condition. Company also has in development miRNA drug for the treatment diseases of CNS. RNatives is also developing engineered exosomes for the delivery of RNA drugs.